{"id":10482,"date":"2020-08-06T14:49:54","date_gmt":"2020-08-06T09:19:54","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=10482"},"modified":"2021-07-24T12:58:03","modified_gmt":"2021-07-24T07:28:03","slug":"recent-pharma-happenings-for-zydus-taysha-dbv-technologies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies","title":{"rendered":"Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV&#8217;s  peanut allergy patch; Combating COVID-19 with decoy target"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69efb7deb31a8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69efb7deb31a8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies\/#Zydus_starts_phase_2_COVID-19_vaccine_trial_after_clearing_safety_test\" >Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies\/#Taysha_raises_USD_95_Million_to_take_4_CNS_gene_therapies_into_the_clinic\" >Taysha raises USD 95 Million to take 4 CNS gene therapies into the clinic<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies\/#Combating_COVID-19_by_luring_the_virus_away_from_human_cells_with_a_decoy_target\" >Combating COVID-19 by luring the virus away from human cells with a decoy target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies\/#FDA_turns_back_peanut_allergy_patch_of_DBV_Technologies\" >FDA turns back peanut allergy patch of DBV Technologies<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zydus_starts_phase_2_COVID-19_vaccine_trial_after_clearing_safety_test\"><\/span><strong>Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Zydus Cadila has finished a phase 1 clinical trial of its <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-therapeutic-pipeline-vaccines\"><strong>COVID-19 vaccine<\/strong><\/a> ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company informed that the DNA vaccine was well tolerated in the first stage of the adaptive phase 1\/2 trial.<\/p>\n\n\n\n<p>ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus. The approach is similar to that pursued by Inovio Pharmaceuticals. Like Inovio, Zydus sees the ability of its vaccine to survive higher temperatures than some rival methods as a differentiator.<\/p>\n\n\n\n<p>Zydus has only said that the vaccine was well tolerated by people who received it in the first phase of the trial. Zydus monitored subjects in a clinical pharmacological unit for 24 hours after dosing and in the community for seven days after that, whether ZyCoV-D works, as well as other <a href=\"https:\/\/www.delveinsight.com\/blog\/covid-19-vaccine-in-india\/\"><strong>COVID-19 vaccine candidates<\/strong><\/a>, remains to be seen.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Taysha_raises_USD_95_Million_to_take_4_CNS_gene_therapies_into_the_clinic\"><\/span><strong>Taysha raises USD 95 Million to take 4 CNS gene therapies into the clinic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Taysha Gene Therapies has raised USD 95 million to take four gene therapies into humans. The series B, which comes months after Taysha&#8217;s USD 30 million seed round, positions ex-AveXis executives to build biotech with a broad gene therapy pipeline and infrastructure to match.<\/p>\n\n\n\n<p>Taysha has moved quickly since disclosing the USD 30 million seed round in April. Taysha informed regarding raise of a USD 95 million Series B round that will enable it to take its lead asset into the clinic this year, file a further three INDs by the end of 2021 and built a commercial-scale production plant.<\/p>\n\n\n\n<p>TSHA-101, a potential treatment for GM2 gangliosidosis, is set to be the first drug to enter the clinic. At the American Society of Gene and Cell Therapy annual meeting in May, UT Southwestern&#8217;s Steven Gray, one of Taysha&#8217;s scientific advisors, and his collaborators showed delivering the gene therapy to mice via a lumbar puncture may improve symptoms at doses low enough to avoid adverse events.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Combating_COVID-19_by_luring_the_virus_away_from_human_cells_with_a_decoy_target\"><\/span><strong>Combating COVID-19 by luring the virus away from human cells with a decoy target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sars-CoV-2, which is behind the <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\"><strong>COVID-19<\/strong><\/a> pandemic, affects a person by initially binding its spike protein to the ACE2 receptor on the human cells&#8217; surface. Stopping this process could theoretically prevent infections when tissues are exposed to the virus.&nbsp;<\/p>\n\n\n\n<p>A research team that is led by the University of Illinois, Urbana-Champaign, purposes that a variant of the receptor that is with one having an even stronger ability to bind to the coronavirus, it might work as a therapeutic candidate against COVID-19 by acting as a decoy to persuade the virus away.<\/p>\n\n\n\n<p>In a new study that is published in Science, the team displayed that one soluble receptor protein, sACE2.v2.4, a variant with three mutations, was considerably more efficient at neutralizing SARS-CoV-2 infection than was the unmodified protein in cultured cells.<\/p>\n\n\n\n<p>Scientists have already isolated many highly potent neutralizing antibodies from patients who recovered from COVID-19. These antibodies defend a cell from infection by squarely preventing the pathogen&#8217;s biological activities. They are considered a viable <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">COVID-19 treatment<\/a><\/strong> approach, and inducing them is a crucial goal of vaccines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_turns_back_peanut_allergy_patch_of_DBV_Technologies\"><\/span><strong>FDA turns back peanut allergy patch of DBV Technologies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-market\"><strong>peanut allergy<\/strong><\/a> patch which is based on new delivery technology has hit a snag at the FDA.<\/p>\n\n\n\n<p>The agency turned down Viaskin Peanut patch of DBV Technologies for children between the ages of 4 and 11 years, raising concerns about the patch itself. Built on the French company&#8217;s Viaskin platform, it is designed to deliver small, controlled amounts of <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-epidemiology-forecast\"><strong>peanut allergens<\/strong><\/a> via skin to desensitize the immune system and lessen its reactions.<\/p>\n\n\n\n<p>As per the statement by DBV, the FDA&#8217;s complete response letter said the design of the patch would require to be modified, with a focus on site adhesion and also how that affects the treatment&#8217;s efficacy.<\/p>\n\n\n\n<p>The company will also have to run a new human factor study and provide supplementary clinical data and information on the patch&#8217;s chemistry and manufacturing as described by the company. The agency raised no safety concerns.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company informed that the DNA vaccine was well tolerated in the first stage of the adaptive [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10485,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18354,420,2193,639,18282,17334],"industry":[17225],"therapeutic_areas":[17227,17231,17243],"class_list":["post-10482","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-covid-19-vaccine","tag-news","tag-peanut-allergy","tag-pharma-news","tag-taysha-gene-therapies","tag-zydus-cadila","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Taysha bags $95M; DBV&#039;s peanut allergy patch; Covid-19 vaccine updates<\/title>\n<meta name=\"description\" content=\"Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Taysha bags $95M; DBV&#039;s peanut allergy patch; Covid-19 vaccine updates\" \/>\n<meta property=\"og:description\" content=\"Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-06T09:19:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/06144651\/news-5.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Taysha bags $95M; DBV's peanut allergy patch; Covid-19 vaccine updates","description":"Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies","og_locale":"en_US","og_type":"article","og_title":"Taysha bags $95M; DBV's peanut allergy patch; Covid-19 vaccine updates","og_description":"Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-08-06T09:19:54+00:00","article_modified_time":"2021-07-24T07:28:03+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/06144651\/news-5.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies","name":"Taysha bags $95M; DBV's peanut allergy patch; Covid-19 vaccine updates","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/06144651\/news-5.jpg","datePublished":"2020-08-06T09:19:54+00:00","dateModified":"2021-07-24T07:28:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-zydus-taysha-dbv-technologies#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/06144651\/news-5.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/06144651\/news-5.jpg","width":772,"height":482,"caption":"Latest-pharma-news-and-updates"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/06144651\/news-5-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID 19 vaccine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">peanut allergy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Taysha Gene Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zydus Cadila<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">COVID 19 vaccine<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">peanut allergy<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Taysha Gene Therapies<\/span>","<span class=\"advgb-post-tax-term\">Zydus Cadila<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 6, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 6, 2020 2:49 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Latest-pharma-news-and-updates","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=10482"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10482\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/10485"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=10482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=10482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=10482"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=10482"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=10482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}